{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:08:08Z","timestamp":1787987288790,"version":"build-2784847793"},"reference-count":40,"publisher":"SLACK, Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Background and Objective<\/jats:title>\n            <jats:p>This was a prospective multicenter, randomized, double-masked, active-controlled study, the aim of which was to demonstrate the efficacy and safety of intravitreal ONS-5010 (bevacizumab-vikg) in eyes with neovascular age-related macular degeneration (nAMD). This was a phase III trial on ONS-5010 (NORSE TWO).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>Treatment-na\u00efve nAMD patients aged 50 years and older with a best-corrected distance visual acuity (BCVA) of 25 to 67 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and evidence of disease activity were included. Patients randomized to ONS-5010 received monthly intravitreal doses of 1.25 mg of ONS-5010, bevacizumab-vikg (Outlook Therapeutics) for 12 months. Patients randomized to ranibizumab received 0.50 mg of ranibizumab on days 0, 30, 60, 150, and 240 based on the PIER study dosing regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              The primary end point was the proportion of patients who gained \u2265 15 letters from baseline in BCVA at 11 months, and evaluating the safety and tolerability of intravitreal injections of ONS-5010 administered monthly from baseline to 12 months. One hundred thirteen participants were included in the ONS-5010 group and 115 participants were included in the ranibizumab group. Respectively, 41.7% and 23.1% of patients gained \u2265 15 letters (3 lines) of visual acuity, with a risk difference of 0.1859 [95% CI = 0.0442, 0.3086];\n              <jats:italic>P<\/jats:italic>\n              = 0.0052. The change in BCVA from baseline to 11 months was found to be 11.2 \u00b1 12.19 and 5.8 \u00b1 14.80 ETDRS letters, respectively. The number of patients gaining \u2265 5 and \u2265 10 letters and patients losing &lt; 15 letters was significantly higher in the ONS-5010 group. Similarly, patients with a Snellen visual acuity equivalent of 20\/200 (35 ETDRS letters) or worse at 11 months were significantly fewer in the ONS-5010 group. Only one patient in the ONS-5010 group had a study-related serious ocular adverse event (SAE), namely, elevated intraocular pressure. The most common adverse event in the ONS-5010 group was conjunctival hemorrhage (8.8%), and reduced visual acuity in the ranibizumab group (12.2%).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In the prescribed treatment plan, ONS-5010 exhibited strong effectiveness in improving or stabilizing visual acuity and was also well tolerated. Bevacizumab and ranibizumab displayed a comparable safety profile.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                [\n                <jats:italic>Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n                2025;56:178\u2013189.]\n              <\/jats:bold>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/23258160-20240924-01","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T15:09:11Z","timestamp":1731510551000},"page":"178-189","source":"Crossref","is-referenced-by-count":5,"title":["ONS-5010 (bevacizumab-vikg) Safety and Efficacy in Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration"],"prefix":"10.3928","volume":"56","author":[{"given":"Firas M.","family":"Rahhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Humayun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena S.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Javid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Jeremiah","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John D.","family":"Pitcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Dagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_2_2_2","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. World report on vision. October 8, 2019. Accessed June 26, 2023. https:\/\/www.who.int\/publications\/i\/item\/9789241516570","journal-title":"World report on vision"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S231913"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(93)31466-1"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2479986"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6823562"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S295223"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40199-015-0110-0"},{"key":"e_1_3_2_9_2","author":"United States Food and Drug Administration","year":"2011","unstructured":"United States Food and Drug Administration. Avastin (bevacizumab) information. June 29, 2011. Accessed June 19, 2023. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/avastin-bevacizumab-information","journal-title":"Avastin (bevacizumab) information"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3928\/1542-8877-20050701-14"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.11.019"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","unstructured":"Dakin HA Wordsworth S Rogers CA IVAN Study Investigators. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open. 2014;4(7):e005094\u2013e005094. 10.1136\/bmjopen-2014-005094 PMID:25079928","DOI":"10.1136\/bmjopen-2014-005094"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.585394"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61501-9"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.015"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.3591"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.11.023"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.5693\/djo.01.2016.03.001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.139"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.04.011"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.002"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153052"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6004047"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.797108"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305327"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31827b6324"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-02998-2"},{"key":"e_1_3_2_31_2","volume-title":"Lytenava, inn-bevacizumab gamma. Appendix I-III","year":"2024","unstructured":"Lytenava, inn-bevacizumab gamma. Appendix I-III. European Medicines Agency; 2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240527162457\/anx_162457_en.pdf"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6431"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d50cea"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000225354.92444.7a"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.86"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181bd2d51"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.07.041"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_802_17"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2010.02054.x"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00307-7"},{"key":"e_1_3_2_41_2","unstructured":"United States Food and Drug Administration. Demonstrating substantial evidence of effectiveness for human drug and biological products - guidance for industry. 2019. Accessed June 26 2023. https:\/\/www.fda.gov\/media\/133660\/download"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T19:02:06Z","timestamp":1741719726000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20240924-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.3928\/23258160-20240924-01"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20240924-01","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}